Objective: The serum albumin-globulin ratio (AGR) is associated with malignancy outcomes. However, among patients with rectal cancer (RC) who undergo neoadjuvant chemoradiotherapy (nCRT), the clinical and prognostic significance of the pretreatment AGR is unclear. Methods: We investigated whether the pre-nCRT AGR can help predict oncological outcomes in patients with RC receiving nCRT. We analyzed 114 patients with RC who received nCRT followed by total mesorectal excision at our institution. Results: A lower AGR in pre-nCRT serum was significantly correlated with shorter overall survival and disease-free survival in patients with nCRT-treated RC. In multivariate analysis, a high carcinoembryonic antigen (CEA) level and a low AGR in pre-nCRT serum were independent predictors of a poor prognosis in these patients. Furthermore, combining the AGR with CEA provided a more accurate indicator of poor prognosis and early recurrence in these patients. In particular, a low pre-nCRT AGR was a stronger indicator of a poor prognosis and early recurrence in patients without than with pathological lymph node metastasis. Combining the pre-nCRT AGR with CEA could more precisely stratify patients’ oncological outcome risks. Conclusion: Assessment of the pretreatment AGR with or without CEA can guide postoperative treatment in patients with RC who undergo nCRT.

Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10–29.
Ludmir EB, Palta M, Willett CG, Czito BG: Total neoadjuvant therapy for rectal cancer: an emerging option. Cancer 2017; 123: 1497–1506.
Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS, Bessell E, Griffiths G, Thompson LC, Parmar M: Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009; 373: 811–820.
Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114–1123.
Cedermark B, Dahlberg M, Glimelius B, Pahlman L, Rutqvist LE, Wilking N: Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336: 980–987.
Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731–1740.
MacFarlane JK, Ryall RD, Heald RJ: Mesorectal excision for rectal cancer. Lancet 1993; 341: 457–460.
Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, Rutten H, Pahlman L, Glimelius B, Leer JW, van de Velde CJ: The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007; 246: 693–701.
Gollins S, Sebag-Montefiore D: Neoadjuvant treatment strategies for locally advanced rectal cancer. Clin Oncol (R Coll Radiol) 2016; 28: 146–151.
Du XJ, Tang LL, Mao YP, Sun Y, Zeng MS, Kang TB, Jia WH, Lin AH, Ma J: The pretreatment albumin to globulin ratio has predictive value for long-term mortality in nasopharyngeal carcinoma. PLoS One 2014; 9:e94473.
Shibutani M, Maeda K, Nagahara H, Ohtani H, Iseki Y, Ikeya T, Sugano K, Hirakawa K: The pretreatment albumin to globulin ratio predicts chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer. BMC Cancer 2015; 15: 347.
Fujikawa H, Toiyama Y, Inoue Y, Imaoka H, Shimura T, Okigami M, Yasuda H, Hiro J, Yoshiyama S, Saigusa S, Kobayashi M, Ohi M, Araki T, Mohri Y, Kusunoki M: Prognostic impact of preoperative albumin-to-globulin ratio in patients with colon cancer undergoing surgery with curative intent. Anticancer Res 2017; 37: 1335–1342.
Zhou T, He X, Fang W, Zhan J, Hong S, Qin T, Ma Y, Sheng J, Zhou N, Zhao Y, Huang Y, Zhang L: Pretreatment albumin/globulin ratio predicts the prognosis for small-cell lung cancer. Medicine 2016; 95:e3097.
Azab BN, Bhatt VR, Vonfrolio S, Bachir R, Rubinshteyn V, Alkaied H, Habeshy A, Patel J, Picon AI, Bloom SW: Value of the pretreatment albumin to globulin ratio in predicting long-term mortality in breast cancer patients. Am J Surg 2013; 206: 764–770.
Oki S, Toiyama Y, Okugawa Y, Shimura T, Okigami M, Yasuda H, Fujikawa H, Okita Y, Yoshiyama S, Hiro J, Kobayashi M, Ohi M, Araki T, Inoue Y, Mohri Y, Kusunoki M: Clinical burden of preoperative albumin-globulin ratio in esophageal cancer patients. Am J Surg 2017; 214: 891–898.
Toiyama Y, Yasuda H, Ohi M, Yoshiyama S, Araki T, Tanaka K, Inoue Y, Mohri Y, Kusunoki M: Clinical impact of preoperative albumin to globulin ratio in gastric cancer patients with curative intent. Am J Surg 2017; 213: 120–126.
Toiyama Y, Shimura T, Yasuda H, Fujikawa H, Okita Y, Kobayashi M, Ohi M, Yoshiyama S, Hiro J, Araki T, Inoue Y, Mohri Y, Kusunoki M: Clinical burden of C-reactive protein/albumin ratio before curative surgery for patients with gastric cancer. Anticancer Res 2016; 36: 6491–6498.
Mohri Y, Tanaka K, Toiyama Y, Ohi M, Ya-suda H, Inoue Y, Kusunoki M: Impact of preoperative neutrophil to lymphocyte ratio and postoperative infectious complications on survival after curative gastrectomy for gastric cancer: a single institutional cohort study. Medicine 2016; 95:e3125.
Mori K, Toiyama Y, Saigusa S, Fujikawa H, Hiro J, Kobayashi M, Ohi M, Araki T, Inoue Y, Tanaka K, Mohri Y, Kusunoki M: Systemic analysis of predictive biomarkers for recurrence in colorectal cancer patients treated with curative surgery. Dig Dis Sci 2015; 60: 2477–2487.
Shirai Y, Okugawa Y, Hishida A, Ogawa A, Okamoto K, Shintani M, Morimoto Y, Nishikawa R, Yokoe T, Tanaka K, Urata H, Toiyama Y, Inoue Y, Tanaka M, Mohri Y, Goel A, Kusunoki M, McMillan DC, Miki C: Fish oil-enriched nutrition combined with systemic chemotherapy for gastrointestinal cancer patients with cancer cachexia. Sci Rep 2017; 7: 4826.
Okugawa Y, Toiyama Y, Toden S, Mitoma H, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A: Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer. Gut 2017; 66: 107–117.
Bozzetti F, Santarpia L, Pironi L, Thul P, Klek S, Gavazzi C, Tinivella M, Joly F, Jonkers C, Baxter J, Gramlich L, Chicharro L, Staun M, Van Gossum A, Lo Vullo S, Mariani L: The prognosis of incurable cachectic cancer patients on home parenteral nutrition: a multi-centre observational study with prospective follow-up of 414 patients. Ann Oncol 2014; 25: 487–493.
Chlebowski RT: Nutrition and physical activity influence on breast cancer incidence and outcome. Breast 2013; 22(suppl 2):S30–S37.
Matsumoto H, Okamoto Y, Kawai A, Ueno D, Kubota H, Murakami H, Higashida M, Hirai T: Prognosis prediction for postoperative esophageal cancer patients using Onodera’s prognostic nutritional index. Nutr Cancer 2017; 69: 849–854.
McMillan DC, Watson WS, O’Gorman P, Preston T, Scott HR, McArdle CS: Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 2001; 39: 210–213.
Asher V, Lee J, Bali A: Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer. Med Oncol 2012; 29: 2005–2009.
Lien YC, Hsieh CC, Wu YC, Hsu HS, Hsu WH, Wang LS, Huang MH, Huang BS: Preoperative serum albumin level is a prognostic indicator for adenocarcinoma of the gastric cardia. J Gastrointest Surg 2004; 8: 1041–1048.
Zhang B, Yu W, Zhou LQ, He ZS, Shen C, He Q, Li J, Liu LB, Wang C, Chen XY, Fan Y, Hu S, Zhang L, Han WK, Jin J: Prognostic significance of preoperative albumin-globulin ratio in patients with upper tract urothelial carcinoma. PLoS One 2015; 10:e0144961.
Liu J, Dai Y, Zhou F, Long Z, Li Y, Liu B, Xie D, Tang J, Tan J, Yao K, Zhang Y, Tang Y, He L: The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy. Urol Oncol 2016; 34: 484.e1–e8.
Sermier A, Gervaz P, Egger JF, Dao M, Allal AS, Bonet M, Morel P: Lymph node retrieval in abdominoperineal surgical specimen is radiation time-dependent. World J Surg Oncol 2006; 4: 29.
Wichmann MW, Muller C, Meyer G, Strauss T, Hornung HM, Lau-Werner U, Angele MK, Schildberg FW: Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer. Arch Surg 2002; 137: 206–210.
Baxter NN, Morris AM, Rothenberger DA, Tepper JE: Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: a population-based analysis. Int J Radiat Oncol Biol Phys 2005; 61: 426–431.
Nagtegaal ID, van de Velde CJ, van der Worp E, Kapiteijn E, Quirke P, van Krieken JH: Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol 2002; 20: 1729–1734.
Rullier A, Laurent C, Capdepont M, Vendrely V, Belleannee G, Bioulac-Sage P, Rullier E: Lymph nodes after preoperative chemoradiotherapy for rectal carcinoma: number, status, and impact on survival. Am J Surg Pathol 2008; 32: 45–50.
Mechera R, Schuster T, Rosenberg R, Speich B: Lymph node yield after rectal resection in patients treated with neoadjuvant radiation for rectal cancer: a systematic review and meta-analysis. Eur J Cancer 2017; 72: 84–94.
Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408–3419.
Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020–2029.
Baddi L, Benson A 3rd: Adjuvant therapy in stage II colon cancer: current approaches. Oncologist 2005; 10: 325–331.
Sun Z, Gilmore B, Adam MA, Kim J, Hsu SD, Migaly J, Mantyh CR: Adjuvant chemother-apy after preoperative chemoradiation improves survival in patients with locally advanced rectal cancer. Dis Colon Rectum 2017; 60: 1050–1056.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.